Patent SG-11201811804Q-A (SG)
Title: Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
Inventor: GODBOUT CÉDRICKX
IPC: C07D498/04
Filed: 2017-07-31
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111111111111111111111111111111111111101111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/024653 Al 08 February 2018 (08.02.2018) W I P0 I P C T (51) International Patent Classification: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, C07D 498/04 (2006.01) A61P 3/04 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, A61K 31/4355 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (21) International Application Number: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, PCT/EP2017/069274 KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: Declarations under Rule 4.17: 31 July 2017 (31.07.2017) — as to applicant's entitlement to apply for and be granted a (25) Filing Language: English patent (Rule 4.1700) (26) Publication Language: English Published: — with international search report (Art. 21(3)) (30) Priority Data: 16183047.6 05 August 2016 (05.08.2016) EP (71) Applicant: BOEHRINGER INGELHEIM INTER- NATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim am Rhein (DE). (72) Inventors: GODBOUT, Cedrickx; Boehringer Ingel- heim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). TRIESELMANN, Thomas; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). VINTONYAK, Viktor; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). (74) Agent: SIMON, Elke et al.; Binger Strasse 173, 55216 In- gelheim am Rhein (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, ,_ 1 (54) Title: OXADIAZOLOPYRIDINE DERIVATES FOR USE AS GHRELIN 0-ACYL TRANSFERASE (GOAT) INHIBITORS (57) : The present invention relates to compounds of general formula en in NH 2 (I), wherein the groups R 1 , R 2 and n are defined as in claim 1, which have valu- able pharmacological properties, in particular bind to ghrelin 0-acyl transferase 71- ei = --.... --.....,- - - - z-, .,'\"--„ , -N.... - : , ,.., (GOAT) and modulate its activity. The compounds are suitable for treatment and N ---- I o (R2), prevention of diseases which can be influenced by this receptor, such as meta- „,.---,. .-:;--.., i X.„ ,::: ,,,-- - -- 1 I NR bolic diseases, in particular obesity. 1-1 (I) 0 ei C